On Monday, E*TRADE Financial Corp (NASDAQ:ETFC)’s shares inclined 2.15% to $26.62.
E*TRADE Financial Corporation (ETFC) released its Monthly Activity Report for August 2015.
Daily Average Revenue Trades for August were 179,908, counting a record trading day for the Company on August 24 with over 394,000 trades. August DARTs represented a 21 percent enhance from July and a 23 percent enhance from the year-ago period. The Company added 37,750 gross new brokerage accounts in August, and ended the month with about 3.2 million brokerage accounts — an enhance of 14,038 from July.
Net new brokerage assets were $1.4 billion in the month. During the month, customer security holdings reduced by six percent, or $11.9 billion, and brokerage-related cash reduced by $0.3 billion to $40.9 billion. Bank-related cash and deposits reduced by $0.1 billion, ending the month at $5.4 billion. Customers were net buyers of about $1.3 billion in securities during the month.
E*TRADE Financial Corporation, a financial services company, provides brokerage and related products and services primarily to individual retail investors under the E*TRADE Financial brand name. It operates through two segments, Trading and Investing, and Balance Sheet Administration.
Devon Energy Corp (NYSE:DVN)’s shares gained 1.38% to $40.33.
Devon Energy Corp. (DVN) declared that its board of directors declared a quarterly cash dividend on Devon’s common stock for the fourth quarter of 2015. The dividend is payable on Dec. 31, 2015, at a rate of $0.24 per share based on a record date of Dec. 15, 2015.
Devon Energy Corporation, an independent energy company, primarily engages in the exploration, development, and production of oil, natural gas, and natural gas liquids (NGLs) in the United States and Canada. It holds interests in various properties located in Anadarko Basin, Barnett Shale, Eagle Ford, Mississippian-Woodford Trend, Permian Basin, and Rockies in the United States, in addition to in the Jackfish and Pike heavy oil projects located in Alberta, Canada.
At the end of Monday’s trade, Interpublic Group of Companies Inc (NYSE:IPG)‘s shares dipped -0.05% to $20.12.
Ranked at the top of our field, Jack Morton is part of the Interpublic Group of Companies, Inc. (IPG). Global brand experience agency Jack Morton Worldwide recently declares a key appointment to its leadership team. Bruce Henderson will join Jack Morton as Chief Creative Officer in January based in the New York office of the agency.
Henderson will leave Geometry Global where he is Chief Creative Officer for North America. Most recently, he guided the merger of the G2, OgilvyAction and JWTAction creative departments, creating Geometry. Preceding to Geometry, Henderson was Group Creative Director at Ogilvy in New York, where he worked on global and US accounts, counting IBM, Siemens, Six Flags, TD Ameritrade and DuPont. Henderson’s work has won numerous awards, counting Clio, Effie, Addy, and Webby Awards.
In addition to charting the agency’s creative vision, Henderson will chair Jack Morton’s global Creative Council, comprised of executive creative directors and senior strategists from across the world, and will oversee the agency’s brand marketing.
The Interpublic Group of Companies, Inc. provides advertising and marketing services. The company operates in two segments, Integrated Agency Netoperates and Constituency Administration Group. It offers consumer advertising, digital marketing, communications planning and media buying, public relations, and specialized communications disciplines.
Idera Pharmaceuticals Inc (NASDAQ:IDRA), ended its Monday’s trading session with -9.26% loss, and closed at $3.43.
Idera Pharmaceuticals, Inc. (IDRA), a clinical-stage biopharmaceutical company developing Toll-like receptor (TLR) and RNA therapeutics for patients with cancer and rare diseases, recently declared new preclinical data that showed cancer immunotherapy with intratumoral injections of IMO-2125 alone and in combination with ipilimumab demonstrated potent and systemic anti-tumor activity in preclinical cancer models. IMO-2125 is a synthetic oligonucleotide-based agonist of Toll-like receptor 9 discovered and developed by Idera. Ipilimumab is a checkpoint inhibitor targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Additionally, Idera presented preclinical data which demonstrated that IMO-2125 induces a systemic antitumor immune response with the potential to sensitize the tumor microenvironment for combination with various checkpoint inhibitors. These data are being presented at the CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference in New York City, starting recently.
Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for oncology and rare diseases in the United States. It uses two proprietary drug discovery technology platforms to design and develop drug candidates, counting toll-like receptor targeting technology and gene silencing oligonucleotide (GSO) technology.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
